IMAGES IN PNEUMONOLOGY
The therapeutic potential of inhaled-GM-CSF in severe a-PAP
 
More details
Hide details
1
2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece
 
2
7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens Greece
 
3
2nd Department of Radiology, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece
 
4
Department of Pediatric Pneumology, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University, German Center for Lung Research, Germany
 
 
Corresponding author
Spyros A. Papiris   

2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece 1 Rimini Street, 12462, Haidari, Greece
 
 
Pneumon 2020;33(2):1-2
 
KEYWORDS
This is to certify that the images have not been previously published and that the patient has provided written permission to publish the case.
 
REFERENCES (5)
1.
Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/ macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181:1345-54.
 
2.
Papiris SA, Tsirigotis P, Kolilekas L, et al. Long-term inhaled Granulocyte Macrophage-Colony Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, safety, lowest-effective dose. Clin Drug Invest 2014; 34:553-64.
 
3.
Papiris SA, Tsirigotis P, Kolilekas L, et al. Pulmonary Alveolar Proteinosis: Time to shift. Expert Rev Respir Med 2015; 9:337-49.
 
4.
Tazawa R, Ueda T, Abe M, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med 2019; 381:923-32.
 
5.
Papiris SA, Griese M, Manali ED. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med 2020; 382:197.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top